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Asthma Management
for Children and Adults
Quick Tips for 
All Patients with Asthma
  Environmental Control: identify and avoid triggers 
such as tobacco smoke, pollens, molds, animal dander, 
cockroaches, and dust mites.
  Flu Vaccine: recommend annually.
  Spirometry: at diagnosis and at least annually.
  Asthma Score: use tools such as ACQ®, ACT™ or ATAQ© to 
assess asthma control.
  Asthma Education: review correct inhaled medication 
device technique every visit, if needed.
  Asthma Action Plan: at diagnosis; review and update at 
each visit.
  Short-Acting Beta-Agonist (e.g., albuterol): 1) for quick 
relief every 4-6 hours as needed (see step 1), 2) pretreat 
with 2 puffs for exercise-induced bronchospasm 10-60 
minutes before exercise.
  Oral Corticosteroids: consider for acute exacerbation.
  Spacer with Valve: if spacer selected, use spacer with 
valve.
  Mask: use with spacer with valve and with nebulizer 
for children <5 years and anyone unable to use correct 
mouthpiece technique.
See www.coloradoguidelines.org for additional asthma management resources.
Consider the diagnosis of “asthma” if:
1.  RECURRENT coughing, wheezing, or shortness of breath relieved by a bronchodilator
2.  Objective response by spirometry (≥12% increase of FEV1 post bronchodilator)
3.  Rule out conditions such as aspiration, GERD, airway anomaly, foreign body, cystic fibrosis, vocal cord dysfunction, or 
COPD.  GERD is a common co-morbidity.  (If diagnosis in doubt, consult with an asthma specialist.)
Assess Asthma Severity:
Persistent vs. Intermittent
1. Symptoms >2 days per week OR
2. Awaken at night from asthma >2X per month OR
3. Limitation of activities, despite pretreatment for exercise induced asthma OR
4. More than 2 steroid bursts in 1 year OR
5. FEV1 <80% predicted OR low FEV1/FVC ratio (see below)
6. For children <4 years consider “persistent” if more than 4 episodes of wheezing in a year 
AND parental history of asthma or eczema or wheezing between illnesses.
Persistent
Asthma
Treatment for Persistent Asthma:
Daily Inhaled Corticosteroids
(steps 2, 3 or higher)
Assess Response within 2-6 weeks
“Well Controlled” Asthma
1. Daytime symptoms <2 days per week AND
2. Awakening at night from asthma <2X per month AND
3. No limitation of activities AND
4. Less than 2 steroid bursts per year
5. FEV1 ≥ 80% predicted
6. FEV1/FVC FEV1/FVC:
5-19 yrs ≥ 85%
20-39 yrs ≥ 80%
40-59 yrs ≥ 75%
60-80 yrs ≥ 70%
Follow the Stepwise 
Approach Guideline 
and consider step down 
if well controlled for 3 
consecutive months.  
Then re-assess every 3 to 
6 months.
Follow the Stepwise 
Approach Guideline 
and step up until well 
controlled is achieved.
Re-assess in 2 to 6 weeks.
YES  NO
Consider referral to a specialist if not well controlled within 
3-6 months using stepwise approach OR 2 or more ED visits 
or hospitalizations for asthma in a year.
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Stepwise Approach
Step 1
(all ages)
Short-acting
beta-agonist (e.g.,
albuterol prn)
If used more than 2 
days per week (other 
than for exercise)
 consider
inadequate control
and the need to
step up treatment.
Step 2
Step 3
Step 4
Step 5
Step 6
Intermittent
Asthma
Persistent Asthma: Daily Medication
All Ages
Preferred:
Low-dose inhaled
steroid
Alternative:
Leukotriene blocker 
or cromolyn
Age 0-4 yrs
Consider referral
(especially if
diagnosis is in
doubt)
Age 12+ yrs
Preferred:
Low-dose inhaled
steroid + long-
acting
beta-agonist or
Medium-dose
inhaled steroid
Alternative:
Low-dose
inhaled steroid +
leukotriene blocker
Age 5-11 yrs
Low-dose inhaled
steroid + long-
acting
beta-agonist
or leukotriene
blocker or
Medium-dose
inhaled steroid
Age 0-4 yrs
Medium-dose 
inhaled steroid + 
referral
Age 12+ yrs
Preferred:
Medium-dose
inhaled steroid +
long-acting beta 
agonist
Alternative:
Medium-dose 
inhaled steroid + 
leukotriene blocker
Age 5-11 yrs
Same as 12+ yrs
Age 0-4 yrs
Medium-dose
inhaled steroid
+
either
long-acting
beta-agonist or
leukotriene
blocker
Age 12+ yrs
High-dose inhaled
steroid + long-
acting
beta-agonist
-and-
Consider
omaluzimab if
allergies
Age 5-11 yrs
Preferred:
High-dose inhaled
steroid + long-
acting
beta-agonist
Alternative:
High-dose
inhaled steroid +
leukotriene blocker
Age 0-4 yrs
High-dose inhaled
steroid
+
either long-acting
beta-agonist or
leukotriene blocker
Age 12+ yrs
High-dose inhaled
steroid + long-
acting beta-agonist
+ oral steroid
-and-
Consider 
omaluzimab if
allergies
Age 5-11 yrs
Preferred:
High-dose inhaled
steroid + long-
acting beta-agonist
Alternative:
High-dose 
inhaled steroid + 
leukotriene blocker
+ 
oral steroid
Age 0-4 yrs
High-dose inhaled
steroid
+
either long-acting
beta-agonist or
leukotriene blocker
+ 
oral steroid
Consider immunotherapy if allergic asthma
All ages Steps 4 through 6: Consult with asthma specialist
Step up as indicated although address possible poor 
adherence to medication.  Re-assess in 2 to 6 weeks.
Step down if well controlled and re-assess in 3 months.  
If very stable then assess control every 3 to 6 months.
All LABAs and combination agents containing LABAs have a black box warning.
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